Cover Image

脊髓性肌萎縮症市場:開發平台分析、市場規模的實際成果&預測、成長率、市場趨勢 (2015-2023年)

Spinal Muscular Atrophy Market - Pipeline Assessment, Size, Growth, Trends, and Forecast 2015 - 2023

出版商 Transparency Market Research 商品編碼 345767
出版日期 內容資訊 英文 44 Pages
商品交期: 最快1-2個工作天內
Back to Top
脊髓性肌萎縮症市場:開發平台分析、市場規模的實際成果&預測、成長率、市場趨勢 (2015-2023年) Spinal Muscular Atrophy Market - Pipeline Assessment, Size, Growth, Trends, and Forecast 2015 - 2023
出版日期: 2015年10月16日 內容資訊: 英文 44 Pages


第1章 簡介

  • 報告概要
  • 調查手法
  • 市場區隔
  • 前提條件

第2章 摘要整理

  • 市場概要

第3章 市場概要

  • 市場定義、概要
  • 脊髓性肌萎縮症:目前治療方法
  • 市場動態
    • 成長推動因素
    • 阻礙成長要素
    • 規定
    • 市場機會
  • 市場魅力度分析

第4章 開發平台分析

  • 脊髓性肌萎縮症:開發平台概要
  • 開發後期的候補藥 (第三階段)
    • ISIS-SMN Rx
  • 開發初期的候補藥 (第1、2相)
    • Olesoxime (TRO19622)
    • LMI070
    • RO6885247
    • CK-2127107
    • scAAV9.CB.SMN
    • RG3039

第5章 建議

第6章 企業簡介

  • AveXis, Inc.
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Isis Pharmaceuticals, Inc.

Pipeline analysis of spinal muscular atrophy (SMA) market report provides with comprehensive analysis of drugs in clinical trials for treatment for spinal muscular atrophy. The report provides insights to SMA prevalence, and current treatment pattern. The report also identifies key market drivers, restraints and opportunities in the global spinal muscular atrophy therapeutics market. Detailed market attractiveness analysis by geography provides future outlook to the spinal muscular atrophy landscape. Market attractiveness analysis considers various factors such as patient population, drug pricing policies, regulatory restrictions, current competition intensity, and current state of healthcare sector for assessing the potential of each geographical market.

In the pipeline analysis of spinal muscular atrophy (SMA) market report, market analysis and forecast has been provided for late stage (phase 3) candidates, while also includes thorough qualitative information for other candidates in early stage (phase 1 and phase 2). ISIS-SMNRx by Isis Pharmaceuticals is presently the only late stage candidate in spinal muscular atrophy pipeline, while three drugs are currently in phase 2 and three others in phase 1. These include Olesoxime (TRO19622), LMI070, RO6885247, CK-2127107, scAAV9.CB.SMN and RG3039. The report also mentions some of the potential preclinical candidates in the spinal muscular atrophy pipeline. The pipeline analysis of spinal muscular atrophy (SMA) market report provides overview of the clinical trials, and its current status for each drug candidate for treatment of spinal muscular atrophy. Details on mergers, acquisitions, licensing agreements, and other collaborative agreements, updated on regulatory policies, and expected study completion are also mentioned in the report. Market estimation and forecast for phase 3 drugs for treatment of spinal muscular atrophy has been provided from the expected year of drug approval, till 2023 (in USD Million) for the United States.

Pipeline analysis of late stage (phase 3) drugs for treatment of spinal muscular atrophy adopts patient based approach, in which actual patient population that can be targeted by the new drug is considered to arrive at probable sales of the drug in the launch year. Forecast model considers various macro- as well as micro-economic factors such as drug efficiency, side effects, prevalence and incidence rate, impact of regulatory policies, impact of competitor drugs and generic competition (if applicable) and pipeline status. The report collates information from various government as well as corporate sources such as Europe and the U.S. clinical trial registries, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), CureSMA, Families of SMA, PubMed, company press releases, annual reports and investor presentations. The analysis also considers inputs from industry experts and key opinion leaders with expertise in rare disease drug discovery, and marketing and sales experts.

Key players with potential candidates in clinical trials for treatment of spinal muscular atrophy have been profiled in the report. These include AveXis, Inc., Cytokinetics, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Isis Pharmaceuticals, Inc. Each of the company profile provides details such as company overview, business overview, financial overview, product portfolio, business strategies, and recent developments.

Table of Contents

Chapter 1 Introduction

  • 1.1 Report Description
  • 1.2 Research Methodology
  • 1.3 Market Segmentation
  • 1.4 Assumptions

Chapter 2 Executive Summary

  • 2.1 Pipeline Analysis: Spinal Muscular Atrophy- Market Snapshot

Chapter 3 Pipeline Analysis: Spinal Muscular Atrophy Market Overview

  • 3.1 Market Definition and Overview
  • 3.2 Current Treatment for Spinal Muscular Atrophy
  • 3.3 Market Dynamics
    • 3.3.1 Drivers
    • 3.3.2 Restraints
    • 3.3.3 Opportunities
  • 3.3 Market Attractiveness Analysis

Chapter 4 : Pipeline Analysis: Spinal Muscular Atrophy

  • 4.1 Spinal Muscular Atrophy: Pipeline Overview
  • 4.2 Late Stage Candidates (Phase 3)
    • 4.2.1 ISIS-SMN Rx
  • 4.3 Early Stage Candidates (Phase 1 and Phase 2)
    • 4.3.1 Olesoxime (TRO19622)
    • 4.3.2 LMI070
    • 4.3.3 RO6885247
    • 4.3.4 CK-2127107
    • 4.3.5 scAAV9.CB.SMN
    • 4.3.6 RG3039

Chapter 5 Recommendation

Chapter 6 Company Profiles

  • 6.1 AveXis, Inc.
  • 6.2 Cytokinetics, Inc.
  • 6.3 F. Hoffmann-La Roche Ltd.
  • 6.4 Novartis AG
  • 6.5 Isis Pharmaceuticals, Inc.
Back to Top